Nosopharm is a biotechnology company based in Lyon, France, focused on researching and developing new anti-infective drugs. Founded in 2009 and led by CEO Philippe Villain-Guillot, it discovered and developed NOSO-502, a first-in-class antibiotic from the Odilorhabdins class for multidrug-resistant hospital-acquired infections. The company has expertise in discovering natural bioactive products from the Xenorhabdus and Photorhabdus microbial genera and in the medicinal chemistry of Odilorhabdins. It has a staff of eight. Nosopharm received a €1.0M interest-free loan from Bpifrance to fund CMC development and regulatory preclinical research for NOSO-502 and to support a clinical trial authorization submission in 2019. The company planned to begin first-in-human trials in 2020. To date it has raised €4.3M in private equity and received €3.8M in grants from Bpifrance, IMI, DGA, Region Languedoc-Roussillon and FEDER. Nosopharm focuses on discovery and development of new antibacterial molecules, notably NOSO-95179, an odilorhabdin-class antibiotic for multidrug-resistant hospital-acquired infections. The company has expertise in discovering natural bioactive products from Xenorhabdus and Photorhabdus genera and in the medicinal chemistry of odilorhabdins. It intends to use recent funding to accelerate regulatory preclinical development of NOSO-95179, which targets Enterobacteriaceae, a WHO priority pathogen. Nosopharm expected to start first-in-man studies in 2019. The company is led by Philippe Villain-Guillot and has a staff of seven. Financially, Nosopharm has combined private equity and grant support alongside the new funding to advance its lead candidate.

Total raised

$4M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Feb 2018